Mariela Militaru

Mariela Militaru


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMariela Militaru
Mariela Militaru
IBIoana-Mădălina Babliuc
Ioana-Mădălina Babliuc
VBVanesa-Larisa Bloaje-Florică
Vanesa-Larisa Bloaje-Florică
VDValentin-Adrian Danci
Valentin-Adrian Danci
IFIulia Filip-Deac
Iulia Filip-Deac
ACAndreea Cătană
Andreea Cătană
Genetic disorders represent a high-impact diagnosis for both patients and their families. Prenatal screening methods and, when recommended, genetic testing allow parents to make informed decisions about the course a pregnancy is going to take. Although offering certainty about the potential evolution and prognosis of the pregnancy, and then the newborn, is usually not possible, genetic counseling can offer valuable insights into genetic disorders. Chromosomal mosaicisms are genetic anomalies that affect only some cell lines in either the fetus or the placenta or both. They can affect autosomal or heterosomal chromosomes, and they can be either numerical or structural. The prognosis seems to be more severe if the genetic alterations are accompanied by malformations visible in ultrasounds. Several genetic techniques can be used to diagnose certain mosaicisms, depending on their nature. A novel approach in prenatal care is non-invasive prenatal screening (NIPS), also known as non-invasive prenatal testing (NIPT), which, although it does not always have diagnostic value, can provide valuable information about potential genetic anomalies, especially numerical, with high sensitivity (Se).

10 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAndreea Catana
Andreea Catana
IIIrina Iordanescu
Irina Iordanescu
GFGheorghe Gerald Filip
Gheorghe Gerald Filip
SFSimona Filip
Simona Filip
MMMariela Militaru
Mariela Militaru
Lorin-Manuel PîrlogLorin-Manuel Pîrlog
Lorin-Manuel Pîrlog
Background. Breast cancer remains a leading cause of cancer-related death among women, with genetic mutations playing a key role. While high-penetrance mutations are well-studied, moderate-to-low-penetrance mutations, which present challenges in clinical decision-making and patient outcomes, are less understood. This study explores the quality of life of breast cancer patients with moderate-penetrance mutations, focusing on the psychosocial and physical consequences of mastectomy and reconstruction to improve patient-centered care. Materials and Methods. A cohort of 620 breast cancer patients treated at Regina Maria Private Health Network, Bucharest, between January 2022 and July 2024 was identified. From this group, 61 patients were selected based on the following criteria: (1) meeting NCCN genetic testing guidelines, (2) carrying moderate-to-low-penetrance mutations, (3) undergoing bilateral mastectomy with double reconstruction, and (4) agreeing to complete a modified version of the BREAST-Q questionnaire. Genetic testing was performed using a 125-gene next-generation sequencing panel. Statistical analyses included non-parametric tests to examine group differences and correlations. Results. Significant correlations were found between several factors. Emotional distress was positively correlated with concerns for family, while couple relationships and financial burden showed a strong positive association. Negative correlations were found between couple relationships and self-concept. Distress levels varied, with “Interference with personal relationships” causing more distress than “Impact on employment”, and financial burden causing more distressing than impact on sexuality. Conclusions. Prophylactic mastectomy significantly reduces cancer risk for women with moderate-penetrance mutations. This study highlights the relationship between surgical choices and quality-of-life factors, advancing personalized prevention strategies and emphasizing patient-centered care.

Verified
Journal Article
Open access
PDF file
CFClaudiu Ioan Filip
Claudiu Ioan Filip
ACAndreea Catana
Andreea Catana
Lorin-Manuel PîrlogLorin-Manuel Pîrlog
Lorin-Manuel Pîrlog
Andrada-Adelaida BelbeAndrada-Adelaida Belbe
Andrada-Adelaida Belbe
MMMariela Militaru
Mariela Militaru
GDGeorge Calin Dindelegan
George Calin Dindelegan
Introduction: This study investigates the distribution and interaction of three polymorphisms—XRCC1 (rs1799782), CHEK2 (rs17879961), and XPD (rs238406)—in Romanian breast cancer patients, aiming to understand their association with histopathological subtypes, age, and BMI. Materials and Methods: This retrospective study analyzed 36 breast cancer patients from a Romanian clinic (2020–2024) with complete genetic data for XRCC1 (rs1799782), CHEK2 (rs17879961), and XPD (rs238406). The patients had invasive, non-metastatic breast cancer and no history of other cancers. Statistical analysis with Jamovi included descriptive stats, McNemar’s test for genotype associations, and multinomial logistic regression to explore links between variants, age, BMI, and tumor subtypes. Results: McNemar tests showed no significant association between XRCC1 and CHEK2 (p = 0.180), nor between XRCC1 and XPD (p = 0.03) or XPD and CHEK2 (p = 0.049) after applying the Bonferroni correction (α = 0.0167), indicating no statistically significant genetic dependency among these variants. A multinomial logistic regression model found that genetic variants, BMI, and age significantly predicted breast cancer subtypes, particularly CDI TNB. All predictors remained significant in the comparisons of CDI TNB vs. CDI LB/CDI LA. Notably, these associations remained unchanged even after applying the Bonferroni correction (α = 0.0021), confirming the robustness of the findings. Conclusions: This study identifies significant associations between XRCC1, CHEK2, and XPD gene variants and CDI TNB, suggesting a role of DNA repair deficiencies in its pathogenesis. Protective genotypes were under-represented in TNB cases. Limited links with luminal subtypes highlight TNB’s distinct genetic profile. Results support further research on these polymorphisms as markers for TNB risk and precision treatment.

31 January 2026 in Genes
Verified
Journal Article
Open access
PDF file
IIIrina Ioana Iordanescu
Irina Ioana Iordanescu
ACAndreea Catana
Andreea Catana
ZCZina Barabas Cuzmici
Zina Barabas Cuzmici
PCPaula Chelu
Paula Chelu
BBBianca Florentina Basangiu
Bianca Florentina Basangiu
MMMariela Militaru
Mariela Militaru
Objectives: This study aimed to characterize the types and frequencies of sex chromosome aneuploidies (SCAs) detected through invasive prenatal testing, evaluate the concordance between non-invasive prenatal testing (NIPT) and confirmatory diagnostic methods, and assess the challenges faced during genetic counseling following SCA diagnosis. Study Design: A retrospective review was conducted on 842 prenatal samples collected between 2020 and 2024 in a tertiary private medical center. Samples included amniotic fluid, chorionic villi, and products of conception. Testing involved rapid QF-PCR for aneuploidy detection, followed by SNP-based chromosomal microarray analysis (CMA). NIPT results with high risk for sex chromosomes aneuploidies were correlated with invasive testing outcomes in 19 cases. Results: Sex chromosome aneuploidies were identified in 67 cases (7.96%), with Turner syndrome (45, X) being the most frequent (23 cases, including six mosaics), followed by Klinefelter syndrome (18 cases), 47, XYY (14 cases), and trisomy X (12 cases). Among 19 NIPT-tested cases, 10 were true positives, 5 false positives, and 4 false negatives, including two mosaic Turner syndrome cases undetected by NIPT. Discordances were attributed to factors such as mosaicism and placental anomalies. Conclusions: Prenatal diagnosis of SCAs via invasive testing remains crucial due to NIPT’s limited sensitivity for mosaicism and false positives. Comprehensive genetic counseling is essential to navigate diagnostic uncertainties and optimize prenatal management and postnatal outcomes.